Adagene (ADAG) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Adagene And 2 Other US Penny Stocks To Consider
Yahoo Finance19:31 ET
Goldman Sachs Raises China Economic Growth Forecasts
WSJOct 13 20:53 ET
China's Stocks Lose Steam as Enthusiasm for Major Stimulus Wanes. What's Next?
Analysts NotebookOct 8 06:04 ET
Today's Pre-Market Movers and Top Ratings | LI, BABA, NKE and More
Movers and ShakersOct 2 08:02 ET
Express News | Hedge Funds Are Pouring Into ETFs Focusing on Chinese Equities With $2.4 Billion Inflows
Moomoo 24/7Oct 2 05:50 ET
Express News | U.S.-Listed Chinese Stocks Surge in Overnight Trading Following Politburo's Commitment to Fiscal Support
Moomoo 24/7Sep 26 02:45 ET

Comments

Jaguar8

Oct 9 07:17

NEWS

$Adagene (ADAG.US)$
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Inc. (Nasdaq: ADAG) has announced upcoming poster presentations at the SITC 39th Annual Meeting in Houston, scheduled for November 6-10, 2024. The presentations will focus on Muzastotug (ADG126), a masked anti-CTLA-4 SAFEbody®.
Two posters will be presented on November 9:
Abstract 506: Comparing the ...

Sean Parker

Sep 16 02:29

News

$Adagene (ADAG.US)$
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
Rhea-AI Impact(Moderate)Rhea-AI Sentiment(Very Positive)TagsRhea-AI SummaryPositiveDoubled confirmed partial responses to four in MSS CRC patients without liver and peritoneal metastases24% overall response rate (ORR) with...

Bigmoney Dreamer

Jan 25 21:31

$Adagene (ADAG.US)$ short trade potential may be upto ⬇️$3 👀

Moomoo AI

Jan 9 04:41

Investors may doubt the sustainability of the strong revenue performance, leading to a low P/S ratio. The company's inferior revenue forecasts compared to the industry and shareholders' acceptance of low future revenue may hinder a strong share price rise.

Adagene Inc. (NASDAQ:ADAG) Shares Fly 40% But Investors Aren't Buying For Growth

Moomoo AI

Oct 7, 2023 06:46

Adagene's P/S is lower than industry peers due to investor skepticism of its high growth projections. The risks putting pressure on Adagene's P/S ratio need scrutiny.

Investors Still Aren't Entirely Convinced By Adagene Inc.'s (NASDAQ:ADAG) Revenues Despite 30% Price Jump

ADAG Adagene

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target